<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2497">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357340</url>
  </required_header>
  <id_info>
    <org_study_id>99-1-103-47429</org_study_id>
    <nct_id>NCT04357340</nct_id>
  </id_info>
  <brief_title>The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19</brief_title>
  <official_title>Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of pulmonary physiotherapy on respiratory
      functions in hospitalized patients with Novel Coronavirus 2019 pneumonia. Patients will be
      randomized into 1) intervention group: receiving pulmonary physiotherapy technique to improve
      pulmonary function and walking training or 2) control group: Usual medical care. Patients in
      both groups will receive therapeutic incentive spirometer. Various outcome measurements of
      pulmonary functions will be evaluated before and after of interventions. Mortality rate,
      hospitalization duration and re-admission will be followed until one month after end of
      intervention. Also, patient's quality of life will be measured after one month.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In late December 2019, the new coronavirus (COVID-19) emerged in Wuhan, China and it has been
      confirmed as the cause of pneumonia in a large number of Chinese patients. The virus, also
      known as SARS-CoV-2, has since then spread to more than 200 countries worldwide.

      The most common symptoms of COVID-19 are fever, dry cough, shortness of breath and tiredness.
      In severe cases, the infection could cause pneumonia, acute respiratory distress syndrome
      (ARDS) and sometimes leads to death. Pulmonary physiotherapy is a comprehensive, effective
      and safe treatment method which is aimed at improving patient's respiratory symptoms, train
      effective coughing, clear the airway secretion, eliminate exacerbation and so on. It seems
      that pulmonary physiotherapy interventions can effectively decrease hospitalization, reduce
      the risk of complications and improve the patient's medical condition.

      The aim of this study is to evaluate the effectiveness of the hold breathing technique, chest
      expansion exercise, postural drainage procedure and Cough techniques carried out during
      pulmonary physiotherapy sessions.

      The researchers will invite 40 hospitalized patients in Imam Khomeini Hospital Complex,
      Tehran, Iran. All patients will be enrolled after taking informed consent. All of the
      procedure will be performed with the coordination of the patient's physicians. Patients will
      be randomized to the intervention or control group. Primary outcome measurements will be
      evaluated immediately before and after the interventions (with three days period). Also,
      patient's condition (including process of disease progression, mortality, hospital stay
      duration and re-admission) will be followed until one month using medical records review and
      interviewing with the patient or his/her family. Patient's health related quality of life
      will be measured using short form-36 quality of life assessment tool one month after the end
      of interventions. Intention-to-treat analysis will be performed in the patients that dropped
      out of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All the enrolled participants will be allocated to the intervention of control groups using blocked-balanced randomization method.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mixed venous O2 pressure (PVO2)</measure>
    <time_frame>Baseline</time_frame>
    <description>Partial pressure of oxygen in mixed venous blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mixed venous O2 pressure (PVO2)</measure>
    <time_frame>Day 3</time_frame>
    <description>Partial pressure of oxygen in mixed venous blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mixed venous CO2 pressure (PVCO2)</measure>
    <time_frame>Baseline</time_frame>
    <description>Partial pressure of carbon dioxide in mixed venous blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mixed venous CO2 pressure (PVCO2)</measure>
    <time_frame>Day 3</time_frame>
    <description>Partial pressure of carbon dioxide in mixed venous blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PH</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of the venous blood acidity or alkalinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PH</measure>
    <time_frame>Day 3</time_frame>
    <description>Measure of the venous blood acidity or alkalinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCO3</measure>
    <time_frame>Baseline</time_frame>
    <description>The amount of bicarbonate ion in the venous blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCO3</measure>
    <time_frame>Day 3</time_frame>
    <description>The amount of bicarbonate ion in the venous blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation (O2 Sat) from VBG</measure>
    <time_frame>Baseline</time_frame>
    <description>The amount of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the venous blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation (O2 Sat) from VBG</measure>
    <time_frame>Day 3</time_frame>
    <description>The amount of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the venous blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Three minute walk test</measure>
    <time_frame>Baseline</time_frame>
    <description>The distance a patient can walk during three minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Three minute walk test</measure>
    <time_frame>Day 3</time_frame>
    <description>The distance a patient can walk during three minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 Sat after one minute walking</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 Sat after one minute walking</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 Sat after two minutes use of Partial Rebreather</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 Sat after two minutes use of Partial Rebreather</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 Sat after two minutes free air breathing</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 Sat after two minutes free air breathing</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 sat/ Fio2</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>O2 sat/ Fio2</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>until one month</time_frame>
    <description>The number of dead subjects compared to total patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Rehospitalization</measure>
    <time_frame>until one moth</time_frame>
    <description>Patients' hospitalization after discharge due to any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Health-Related Quality of Life (HRQOL)</measure>
    <time_frame>One month after end of intervention</time_frame>
    <description>Using Short-form 36 questionnaire. The minimum score is 0 and the maximum score is 100. Higher scores mean patient's better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breathlessness</measure>
    <time_frame>Baseline</time_frame>
    <description>The amount of shortness of breath using Visual Analogue Scale (VAS). The minimum score is 0 and maximum is 10. The 0 score means no breathlessness and the 10 score is the maximum breathlessness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breathlessness</measure>
    <time_frame>Day 3</time_frame>
    <description>The amount of shortness of breath using Visual Analogue Scale (VAS). The minimum score is 0 and maximum is 10. The 0 score means no breathlessness and the 10 score is the maximum breathlessness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Covid-19</condition>
  <condition>Pneumonia</condition>
  <condition>SARS Pneumonia</condition>
  <arm_group>
    <arm_group_label>Pulmonary Physiotherapy Techniques group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary physiotherapy techniques, 6 sessions during 3 days and incentive spirometer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Incentive spirometer only</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary Physiotherapy Techniques</intervention_name>
    <description>Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).</description>
    <arm_group_label>Pulmonary Physiotherapy Techniques group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with COVID-19 pneumonia confirmed by RT-PCR test and diagnostic radiology.

          2. Non-intubated patients

          3. Patients with full consciousness

          4. Be able to walking and performing exercises.

          5. O2 Saturation &lt; 88% when free air breathing.

          6. be able to write and read in Farsi

        Exclusion Criteria:

          1. Any type of musculoskeletal disorder disabling patient to participate to study.

          2. Intubation during the period of intervention

          3. Patients' dissatisfaction to continue the study for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Javaherian, Ph.D. cand.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imam Khomeini Hospital Complex</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.</citation>
    <PMID>31978945</PMID>
  </reference>
  <reference>
    <citation>Read JM, Bridgen JR, Cummings DA, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. MedRxiv. 2020.</citation>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020 Mar;22(2):69-71. doi: 10.1016/j.micinf.2020.01.004. Epub 2020 Feb 4.</citation>
    <PMID>32032682</PMID>
  </reference>
  <reference>
    <citation>Liu T, Hu J, Kang M, Lin L, Zhong H, Xiao J, et al. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). 2020.</citation>
  </reference>
  <reference>
    <citation>Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.</citation>
    <PMID>31995857</PMID>
  </reference>
  <reference>
    <citation>Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R, Harvey A, Hughes T, Lincoln M, Mikelsons C, Potter C, Pryor J, Rimington L, Sinfield F, Thompson C, Vaughn P, White J; British Thoracic Society Physiotherapy Guideline Development Group. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax. 2009 May;64 Suppl 1:i1-51. doi: 10.1136/thx.2008.110726.</citation>
    <PMID>19406863</PMID>
  </reference>
  <reference>
    <citation>Strickland SL, Rubin BK, Haas CF, Volsko TA, Drescher GS, O'Malley CA. AARC Clinical Practice Guideline: Effectiveness of Pharmacologic Airway Clearance Therapies in Hospitalized Patients. Respir Care. 2015 Jul;60(7):1071-7. doi: 10.4187/respcare.04165.</citation>
    <PMID>26113566</PMID>
  </reference>
  <reference>
    <citation>Yang F, Liu N, Hu JY, Wu LL, Su GS, Zhong NS, Zheng ZG. [Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV)]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):180-182. doi: 10.3760/cma.j.issn.1001-0939.2020.03.007. Chinese.</citation>
    <PMID>32164083</PMID>
  </reference>
  <reference>
    <citation>Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, Hao SR, Jia HY, Cai H, Zhang XL, Yu GD, Xu KJ, Wang XY, Gu JQ, Zhang SY, Ye CY, Jin CL, Lu YF, Yu X, Yu XP, Huang JR, Xu KL, Ni Q, Yu CB, Zhu B, Li YT, Liu J, Zhao H, Zhang X, Yu L, Guo YZ, Su JW, Tao JJ, Lang GJ, Wu XX, Wu WR, Qv TT, Xiang DR, Yi P, Shi D, Chen Y, Ren Y, Qiu YQ, Li LJ, Sheng J, Yang Y. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-1009. doi: 10.1136/gutjnl-2020-320926. Epub 2020 Mar 24.</citation>
    <PMID>32213556</PMID>
  </reference>
  <reference>
    <citation>Novoa N, Ballesteros E, Jiménez MF, Aranda JL, Varela G. Chest physiotherapy revisited: evaluation of its influence on the pulmonary morbidity after pulmonary resection. Eur J Cardiothorac Surg. 2011 Jul;40(1):130-4. doi: 10.1016/j.ejcts.2010.11.028. Epub 2011 Jan 11.</citation>
    <PMID>21227711</PMID>
  </reference>
  <reference>
    <citation>Ambrosino N, Makhabah DN. Comprehensive physiotherapy management in ARDS. Minerva Anestesiol. 2013 May;79(5):554-63. Epub 2013 Jan 10. Review.</citation>
    <PMID>23306398</PMID>
  </reference>
  <reference>
    <citation>Munshi L, Kobayashi T, DeBacker J, Doobay R, Telesnicki T, Lo V, Cote N, Cypel M, Keshavjee S, Ferguson ND, Fan E. Intensive Care Physiotherapy during Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome. Ann Am Thorac Soc. 2017 Feb;14(2):246-253. doi: 10.1513/AnnalsATS.201606-484OC.</citation>
    <PMID>27898220</PMID>
  </reference>
  <reference>
    <citation>Paulus F, Binnekade JM, Vroom MB, Schultz MJ. Benefits and risks of manual hyperinflation in intubated and mechanically ventilated intensive care unit patients: a systematic review. Crit Care. 2012 Aug 3;16(4):R145. doi: 10.1186/cc11457. Review.</citation>
    <PMID>22863373</PMID>
  </reference>
  <reference>
    <citation>Hillegass E. Essentials of Cardiopulmonary Physical Therapy-E-Book: Elsevier Health Sciences; 2016.</citation>
  </reference>
  <reference>
    <citation>Iriberri M, Gáldiz JB, Gorostiza A, Ansola P, Jaca C. Comparison of the distances covered during 3 and 6 min walking test. Respir Med. 2002 Oct;96(10):812-6.</citation>
    <PMID>12412981</PMID>
  </reference>
  <reference>
    <citation>Pan AM, Stiell IG, Clement CM, Acheson J, Aaron SD. Feasibility of a structured 3-minute walk test as a clinical decision tool for patients presenting to the emergency department with acute dyspnoea. Emerg Med J. 2009 Apr;26(4):278-82. doi: 10.1136/emj.2008.059774.</citation>
    <PMID>19307390</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>May 30, 2020</last_update_submitted>
  <last_update_submitted_qc>May 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mohammad Javaherian</investigator_full_name>
    <investigator_title>PhD. Candidate of Phyiotherapy</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Physiotherapy</keyword>
  <keyword>2019 novel coronavirus disease</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underline the results reported in this article, after de-identification</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 12 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide an approved methodologically proposal in the same purpose</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

